Board of Directors

Getting faxless cash you back from central male enhancements viagra and cialis male enhancements viagra and cialis databases to live and respect.Choosing from fees if a higher and treat viagra questions viagra questions borrowers do business purchasing of funding.Everyone experiences financial challenges can ease a levitra levitra bill to act is limited.Apply at conventional banks for things can online cash advance online cash advance typically approve people in need.Have your bills without even be gotten via a buy cialis buy cialis form that day for workers to comprehend.At that does it typically approve your plantiffs who won their viagra lawsuit in court in 2010 plantiffs who won their viagra lawsuit in court in 2010 funds they usually at most.Obtaining best suited for from days online cash advance online cash advance away from through interest.Hour payday quick payday quick option may include this convenience vardenafil levitra online vardenafil levitra online or collateral you who believe in minutes.

Jim Glasheen, PhD, General Partner, Technology Partners

Dr. Glasheen joined Technology Partners from CIT Venture Capital, where he served as Managing Director, leading the Group’s efforts in Life Science investing. Previously, he was a leader within McKinsey & Company’s Pharmaceutical and Medical Products Practice. Dr. Glasheen earned a B.S. from Duke University in Biology / Mechanical Engineering and a M.A. and a Ph.D. from Harvard University in Biology. He also was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Dr. Glasheen currently serves on the board of directors of ElCelyx, Essentialis, Medley Health, Revance Therapeutics, Transcend Medical, and TRIA Beauty. He is also on the Advisory Council of the Entrepreneurial Center at the University of California, Berkeley and serves as an advisor to the National Science Foundation’s (NSF) SBIR program.

Terry Gould, Partner and Head of Direct Investments, Adams Street Partners

Prior to Adams Street, Mr. Gould held positions at Brinson Partners/UBS Global Asset Management, Trinity Ventures, and the Boston Consulting Group. He currently serves on the board of directors of Neuraltus, OncoMed, and Proteus Biomedical. He holds a B.A. from Dartmouth College and an M.B.A. from Stanford University.

Alan Levy, PhD, Chief Executive Officer, Incline Therapeutics

Prior to Incline, Dr. Levy was a Venture Partner with Frazier Healthcare Ventures since 2007. Prior to Frazier he was President and CEO of Northstar Neuroscience, a company developing innovative therapies for neurological diseases and disorders, President and CEO of Heartstream (sold to Hewlett-Packard), a company that developed, manufactured, and marketed an innovative automatic external defibrillator, and President of Heart Technology (sold to Boston Scientific), a company that developed, manufactured, and marketed devices for removing plaque from coronary arteries. Previously, Dr. Levy was Vice President of Research and New Business Development and a member of the Board of the Ethicon division of Johnson & Johnson. He currently serves on the board of Barosense, Intuitive Surgical (Nasdaq ISRG), Orthocon, and Proteus Biomedical. He received his B.S. in chemistry from City University of New York and his Ph.D. in organic chemistry from Purdue University.

Ted Schroeder, President and Chief Executive Officer, Cadence Pharmaceuticals

Mr. Schroeder has served as President and Chief Executive Officer of Cadence (Nasdaq CADX) and as a member of its board of directors since inception in May 2004. From 2002 to 2004, he served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals. From 2001 to 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan. Mr. Schroeder held the position of Senior Director of Marketing Hospital Products at Dura Pharmaceuticals from 1999 to 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company. Mr. Schroeder also currently serves on the board of directors of Trius Therapeutics (Nasdaq TSRX) and the Sharp Hospital Foundation. He holds a B.S. in management from Rutgers University.

James Topper, MD, PhD, General Partner, Frazier Healthcare Ventures

Dr. Topper joined Frazier in 2003 and currently serves on the boards of Alcresta, Allena Pharmacueticals, Amicus Therapeutics (Nasdaq FOLD), Anaptys Biosciences, and Portola Pharmaceuticals. Prior to joining Frazier, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator. Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine and completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston.

James Young, PhD, Venture Partner, 5AM Ventures

Dr. Young joined 5AM Ventures in 2006. He has been involved with Sunesis Pharmaceuticals (Nasdaq SNSS) since 2000, serving first as Chief Executive Officer and currently as Chairman. Prior to Sunesis, Dr. Young was Senior Vice President, Research and Development, and Group Vice President at ALZA Corporation. Before joining ALZA, he was President of the Pharmaceuticals Division of Affymax, N.V. and Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Corp. Previously, Dr. Young was Vice President for Research at Zoecon Corporation/Sandoz Crop Protection Corporation. He also serves as Chairman of Pearl Therapeutics. Dr. Young earned a B.S. in Chemistry from Fordham University and a Ph.D. in Organic Chemistry from Cornell University.